MedinCell SA (MEDCL) AI Stock Analysis

• Market Cap: €683.04M
• Dividend Yield: N/A
• Average Volume (3M): 103.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.65
• Revenue Growth: 181.43%
• EPS Growth: 28.76%
• Country: FR
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 33,097,286
• 10 Day Avg. Volume: 145,865
• 30 Day Avg. Volume: 103,800
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €25.60
• Price Target Upside: 21.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 53 Neutral
• Price Target: €18.00 ▼(-14.69% Downside)

The overall stock score of 53 reflects strong technical momentum, which is offset by significant financial performance challenges and poor valuation metrics. While the stock shows positive price trends, the underlying financial instability and lack of profitability are major concerns.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product adoption, which can lead to sustainable long-term expansion and increased market share.

Partnerships and Collaborations

Strategic partnerships provide financial backing, market access, and distribution networks, enhancing MedinCell's ability to commercialize its technologies and drive future growth.

Cash Generation Ability

Positive operating cash flow indicates effective cash management and operational efficiency, supporting the company's ability to fund ongoing operations and invest in growth opportunities.

Negative Factors

Profitability Challenges

Persistent negative margins highlight ongoing operational challenges and cost management issues, which can hinder long-term financial stability and growth potential.

High Leverage

High leverage poses financial risk and limits flexibility, potentially impacting the company's ability to invest in growth initiatives and weather economic downturns.

Negative Equity

Negative equity is a concerning sign of financial instability, indicating that the company may face difficulties in meeting its obligations and sustaining operations long-term.

MedinCell SA Business Overview & Revenue Model

Company Description

MedinCell SA (MEDCL) is a biotechnology company based in France, specializing in the development of long-acting injectable drug delivery systems. The company focuses on innovative formulations and technologies that enhance the therapeutic efficacy and patient compliance of existing medicines. MedinCell operates primarily in the pharmaceutical sector, working on various therapeutic areas including pain management, contraception, and mental health, with a pipeline of products designed to improve the delivery and effectiveness of drugs.

How the Company Makes Money

MedinCell generates revenue primarily through partnerships and collaborations with pharmaceutical companies for the development and commercialization of its proprietary drug delivery technologies. The company often enters into licensing agreements, where it receives upfront payments, milestone payments based on the achievement of development and regulatory targets, and royalties on future sales of the products developed using its technology. Significant partnerships with established pharmaceutical firms are crucial for MedinCell's revenue model, as they provide not only financial backing but also access to broader markets and distribution networks. Additionally, the company may also generate revenue through research and development services provided to partners, further diversifying its income streams.

MedinCell SA Financial Statement Overview

Summary

MedinCell SA is experiencing robust revenue growth but faces significant challenges in achieving profitability and maintaining financial stability. High leverage and negative equity pose risks, while cash flow generation provides some relief. Improvement in operational efficiency and debt management is needed.

Income Statement

MedinCell SA has shown significant revenue growth of 93.49% in the latest year, indicating strong top-line expansion. However, the company is struggling with profitability, as evidenced by negative net profit margins (-72.19%) and EBIT margins (-51.64%). The consistent negative margins highlight ongoing operational challenges and cost management issues.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of -3.59, indicating significant leverage and potential financial risk. The negative stockholders' equity suggests that liabilities exceed assets, which is a concerning sign of financial instability. Return on equity is positive at 112.65%, but this is due to negative equity, which distorts the metric.

Cash Flow

The cash flow statement shows a decrease in free cash flow growth (-15.33%), but the company has managed to generate positive operating cash flow. The free cash flow to net income ratio of 0.91 suggests that the company is generating cash relative to its net losses, which is a positive aspect amidst overall cash flow challenges.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	13.20M	25.54M	9.16M	9.94M	4.09M	8.19M
Gross Profit	12.87M	25.54M	9.16M	9.94M	4.09M	6.74M
EBITDA	-18.81M	-11.20M	-18.61M	-26.41M	-21.45M	-18.12M
Net Income	-31.45M	-18.44M	-25.04M	-32.01M	-24.81M	-19.02M
Balance Sheet
Total Assets	58.86M	90.45M	36.95M	29.34M	44.30M	63.61M
Cash, Cash Equivalents and Short-Term Investments	38.85M	71.90M	19.46M	6.47M	26.59M	49.87M
Total Debt	59.60M	58.76M	58.96M	57.71M	47.49M	43.34M
Total Liabilities	112.89M	106.82M	77.77M	71.63M	57.67M	54.69M
Stockholders Equity	-54.03M	-16.37M	-40.82M	-42.29M	-13.37M	8.92M
Cash Flow
Free Cash Flow	21.03M	17.80M	-13.11M	-22.03M	-23.34M	-12.96M
Operating Cash Flow	21.40M	19.46M	-11.92M	-21.00M	-21.36M	-12.14M
Investing Cash Flow	-7.42M	-13.21M	-613.00K	1.30M	-316.00K	-1.06M
Financing Cash Flow	-9.13M	33.32M	25.53M	1.56M	-800.00K	47.92M

MedinCell SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 21.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:MEDCL, the sentiment is Positive. The current price of 21.1 is above the 20-day moving average (MA) of 18.30, above the 50-day MA of 17.21, and above the 200-day MA of 15.91, indicating a bullish trend. The MACD of 0.98 indicates Negative momentum. The RSI at 80.11 is Negative, neither overbought nor oversold. The STOCH value of 88.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:MEDCL.

MedinCell SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABVX	58 Neutral	5.24B	-25.01	-434.26%	―	0.00%	18.52%
VLA	58 Neutral	721.27M	-10.34	-35.96%	―	30.21%	-76.83%
MEDCL	53 Neutral	€683.04M	―		―	181.43%	28.76%
DBV	50 Neutral	219.85M	-1.58	0.00%	―	0.00%	-20.97%
NANO	48 Neutral	434.23M	-14.68	103.70%	―	0.00%	0.00%
IVA	46 Neutral	609.41M	-1.46	172.73%	―	-47.37%	-26.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%